Neurosterix Secures $105Mn to Advance Treatments for Schizophrenia and Anxiety

The funding round was led by RTW Investments. New investors included Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors and Dellora Investments. Existing investors Perceptive Advisors and Acorn Bioventures also took part.

“The clinical validation of muscarinic biology has created an important opportunity to develop the next generation of treatments for schizophrenia and other serious neuropsychiatric disorders,” said Fred Callori, Chief Executive Officer of Neurosterix. “We believe Neurosterix is entering a defining stage in its development with NTX-253, our selective M4 allosteric modulator, as we prepare to enter Phase 2 clinical development. With the support of an exceptional investor syndicate and the addition of Andrew, Ed and Steve, we now have the resources and expertise to advance our clinical programs and pursue our broader ambition of building a leading neuropsychiatric company.”

“Muscarinic therapies have opened an important new chapter in the treatment of schizophrenia as the first ever non-dopamine-based treatments, which will bring multiple new treatment options for patients,” said Andrew Miller, Ph.D., Executive Chair of Neurosterix. “I believe Neurosterix’s highly selective approach to M4 modulation has the opportunity to be an important next generation muscarinic treatment building on promising early clinical findings and I look forward to working with the team to advance NTX-253 and help build Neurosterix into a leading company in neuropsychiatric therapeutics with a broader discovery platform capable of generating differentiated therapies.”

Neurosterix is a biotechnology company developing new medicines for mental health conditions. It uses a research approach called allosteric modulation, which aims to adjust how signals work in the brain. The company hopes this approach will help create safer and more effective treatments.

Its research focuses on conditions such as schizophrenia, mood disorders and anxiety. The company is developing three potential medicines: NTX-253 for schizophrenia, NTX-819 for mood and anxiety disorders, and NTX-529 for other conditions linked to psychosis and mood disorders.

Through these medicines, Neurosterix aims to improve treatment options for people living with mental health conditions. The company operates in Boston, United States, and Geneva, Switzerland.

Read Also- Pro Climbing League Raises €3.8Mn in Seed Funding to Take Professional Climbing Global